DC based vaccines expressing the tumor antigens PSA or Her2/neu

Protein expression data is available for our pre-clinical work aiming at developing DC based vaccines expressing the tumor antigens PSA or Her2/neu. Monocyte rich fractions were produced by elutriation under GMP conditions and cultured for 5 days with GM-CSF and IL-4. Conditions for transfection with electroporation (Amaxa) or with Adenovirus constructs have been established. Protein expression (Her2/neu, PSA) following transfection with a panel of different full length or truncated Her2/neu or PSA constructs was assessed using Facs analysis (Her2/neu) or assessment of soluble protein (PSA).

Work in progress is investigating conditions for stimulating CD4 and CD8 T cell responses with the transfected DCs, matured for 2 days in poly I:C. The activation status of CD4+/CD25+ T reg in TIL in prostate cancer has been analysed. A higher frequency of CD4+/CD25+/GITR+/ICOS+/FoxP3+ cells in the areas with malignancy as compared to normal prostate tissue or peripheral blood of patients with prostate cancer was found.

• stimulus type
• dendritic cell

• organ type
• prostate

• molecule type
• HER-2,
• CD8,
• Inducible T-cell co-stimulator,
• FOXP3 gene,
• glucocorticoid-induced tumor necrosis factor receptor,
• Granulocyte macrophage colony-stimulating factor,
• Interleukin-4,
• Phosphoserine aminotransferase,
• CD25 receptor,
• transcription factor IRF-8,
• Polyinosinic acid:polycytidylic acid,
• CD4

• cell type
• dendritic cell,
• regulatory t cell,
• monocyte

• organism type
• unidentified adenovirus

created over 16 years ago (2 March 2009)    last modified over 12 years ago (3 September 2012)   [ RDF ]   [ RelFinder ]